GlassScriptPhysician profile
Lalisa Greene Carpenter
NPI 1508860271
$2,044.86
in general payments reported to CMS, 2019-2025
19 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.67 · 2022: $181 · 2023: $38.31 · 2024: $148 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $445.97 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $366.45 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $219.93 | 2025 | |
| Pfizer INC. | $208.64 | 2025 | |
| Axsome Therapeutics, INC. | $117.36 | 2024-2025 | Auvelity |
| Dexcom, INC. | $97.64 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $94.38 | 2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $72.92 | 2022-2025 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $64.97 | 2025 | Voquezna |
| Bausch Health US, LLC | $59.31 | 2024-2025 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $56.79 | 2025 | Vaxneuvance, Capvaxive, Enflonsia |
| Abbott Laboratories | $51.50 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.52 | 2025 | Caplyta |
| Lilly USA, LLC | $33.25 | 2025 | Zepbound, Mounjaro |
| Viatris Specialty LLC | $29.78 | 2025 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.23 | 2025 | |
| Verona Pharma, INC. | $22.89 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $20.95 | 2025 | Rexulti |
| Corium, LLC | $17.38 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalisa Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.